Kodiak Sciences Stock News

A disappointing clinical trial result is weighing heavily on the drugmaker's shares today.

Disappointing drug trial results have sent Kodiak Sciences and shares of KOD stock plunging more than 80% in today's trading session. The post KOD Stock Alert: Why Is Kodiak Sciences Plunging 80% Toda

Investors are trying to take a longer-term view on the geopolitical situation.

KSI-301 has shown higher retinal bioavailability and longer half-life than the comparator for this Phase 3 trial, the blockbuster drug Eylea (Aflibercept).

Barclays has lowered the firm's price target on Kodiak Sciences Inc KOD to $50 from $81 and keeps an Underweight rating on the shares, representing an almost 20% downside. Get the Inside Access T

Kodiak Sciences (KOD) has enrolled more than 900 patients in two phase III studies evaluating its VEGF inhibitor in patients with DME.

Kodiak Sciences Inc (KOD) shares closed 0.5% lower than its previous 52 week low, giving the company a market cap of $3B. The stock is currently down 20.5% year-to-date, down 55.4% over the past 12 months, and up 563.5% over the past five years. This week, the Dow Jones Industrial Average fell 1.4%, and the S&P 500 fell 1.6%. Trading Activity Trading volume this week was 56.0% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 2.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -3489.9% The company's stock price performance over the past 12 months lags the peer average by 93.0% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Kodiak Sciences Inc (KOD) shares closed 2.3% lower than its previous 52 week low, giving the company a market cap of $3B. The stock is currently down 14.8% year-to-date, down 53.0% over the past 12 months, and up 610.7% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 31.5% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 832.0% The company's stock price performance over the past 12 months lags the peer average by 76.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Kodiak Sciences Inc (KOD) shares closed today at 1.6% above its 52 week low of $71.04, giving the company a market cap of $3B. The stock is currently down 14.8% year-to-date, down 51.0% over the past 12 months, and up 610.7% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 8.4% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 2.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 10.2% lower than its 5-day moving average, 16.0% lower than its 20-day moving average, and 27.6% lower than its 90-day moving average. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 1669.5% The company's stock price performance over the past 12 months lags the peer average by 70.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Kodiak Sciences (KOD) progresses well with the development of its lead candidate, KSI-301, for treating various retinal vascular diseases. Stiff competition in the target market remains a woe.

Kodiak Sciences (KOD) reports wider-than-expected loss for the third quarter of 2021. Pipeline development remains in focus for the company.

When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock.

Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock?

PALO ALTO, Calif. , Sept. 1, 2021  /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics

PALO ALTO, Calif., Aug. 31, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to